评估血糖危险指数的临床实用性
Agatha F Scheideman1, Mandy M Shao1, Yijiong Yang2
1Diabetes Technology Society, Burlingame, CA, USA.
Journal of diabetes science and technology
|November 11, 2025
概括
血糖风险指数 (GRI) 是解释持续血糖监测 (CGM) 数据的宝贵工具,有助于医疗保健专业人员在糖尿病管理中. 它的整合到临床实践是有希望的,尽管需要进一步的标准化和培训.
科学领域:
- 糖尿病管理和技术.
- 临床决策支持系统临床决策支持系统
- 血糖控制评估评估 血糖控制评估
背景情况:
- 血糖危险指数 (GRI) 提供了一个复合得分,以简化持续血糖监测 (CGM) 的解释.
- 它将低血糖,高血糖和葡萄糖变化的风险量化成一个单一的指标.
- 作为决策支持工具的GRI的临床实用性需要进一步研究.
研究的目的:
- 评估医疗保健专业人员对GRI的看法.
- 在临床实践中评估GRI的感知有用性,优势和局限性.
- 探索将GRI整合到糖尿病护理工作流程中的可能性.
主要方法:
- 一项观察性研究涉及28名糖尿病护理和教育专家 (DCES) 和其他医疗保健专业人员 (HCP).
- 参与者参加了关于GRI的虚拟教育会议,随后进行了在线调查.
- 调查数据包括人口统计,工具偏好 (GRI与GRI). 流动性葡萄糖概况 (AGP),以及关于GRI有用性的反,并以主题分析的定性响应.
主要成果:
- 大多数参与者更喜欢与AGP一起使用GRI来评估血糖管理.
- 75%的参与者表示愿意将GRI整合到他们的临床工作流程中.
- 参与者对GRI的优点 (4.57 ± 0.84) 和对从业者的有用性评价很高,对缺点 (3.04 ± 1.20) 有中度的担忧.
- 确定的主要主题是GRI能够简化数据,帮助临床决策,改善CGM数据的理解,以及更广泛传播的需要.
结论:
- GRI被认为是传统的CGM报告的宝贵补充,增强了临床评估和糖尿病教育.
- 对于更广泛的GRI集成存在很高的热情,但标准化,准则采用和医疗保健人员培训等障碍需要解决.
- 未来的研究应该集中在GRI对临床结果和最佳实施策略的影响上.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Hypoglycemia and Glucagon
787
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
787
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
392
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
392
Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577
Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
Therapeutic Index
6.5K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.5K


